NCT00564330

Brief Summary

Dental erosions in 30 male and female patients with proven abnormal gastrooesophageal reflux will be assessed clinically and using a novel optical coherence tomography (OCT) laser technique before and after double-blind randomization to antisecretory treatment with esomeprazole 20mg or placebo bid for 3 weeks. The primary objective is to quantify tooth substance loss as well as changes in optical reflectance and scattering of dental hard tissues with and without acid inhibition. Secondary objectives are: To compare standardised visual scoring with OCT quantification of reflux damage at the different time points on different teeth. To assess sex differences in OCT- quantified dental tissue loss.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Nov 2007

Shorter than P25 for phase_1

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

November 26, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 27, 2007

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2008

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2008

Completed
Last Updated

August 26, 2014

Status Verified

August 1, 2014

Enrollment Period

5 months

First QC Date

November 26, 2007

Last Update Submit

August 25, 2014

Conditions

Keywords

dental erosionOCTproton pump inhibitor

Outcome Measures

Primary Outcomes (1)

  • Dental erosions by OCT

    3 weeks

Secondary Outcomes (1)

  • OCT parameters

    3 weeks

Study Arms (2)

esomeprazole

ACTIVE COMPARATOR

Esomeprazole 20mg twice daily

Drug: Esomeprazole

placebo

PLACEBO COMPARATOR

Placebo tablet twice daily

Drug: Placebo

Interventions

20mg bid

Also known as: Nexium
esomeprazole

Placebo bid

placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Dental erosions with Lussi score greater than 1, diagnosed by dentist
  • Provision of informed consent
  • Male or female aged 18 or above years
  • GORD defined by time with pH\<4 greater than 3.5% during 24 hours demonstrated by 24h-hour pH-metry in the last 6 months before the start of the study

You may not qualify if:

  • Significant illness within 2 weeks of study begin as judged by investigator.
  • Established or suspected non-reflux causes for dental erosions.
  • Inability or unwillingness to give informed consent.
  • Inability to attend all study.
  • New dental treatment (including dental products) may not be begun from 2 weeks before study begin until the end of the study, except usual dental hygiene with usual toothpaste.
  • Allergy to or other contraindication for treatment with esomeprazole.
  • Substantial change or planned change in dietary pattern, esp. diets within 2 weeks of study start and for the duration of the entire study.
  • Change or planned change in normal medication or use of herbal, mineral, vitamin preparations within 2 weeks of study start and until the end of the study.
  • Congenital dental defects.
  • Ongoing pregnancy or breast-feeding.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Tooth Erosion

Interventions

Esomeprazole

Condition Hierarchy (Ancestors)

Tooth DemineralizationTooth DiseasesStomatognathic DiseasesTooth Wear

Intervention Hierarchy (Ancestors)

Omeprazole2-PyridinylmethylsulfinylbenzimidazolesSulfoxidesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Clive H. Wilder-Smith, MD

    Brain-Gut Research Group

    PRINCIPAL INVESTIGATOR
  • Petra Wilder-Smith, Professor

    Beckman and Laser Institute, University of California, Irvine, USA

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 26, 2007

First Posted

November 27, 2007

Study Start

November 1, 2007

Primary Completion

April 1, 2008

Study Completion

May 1, 2008

Last Updated

August 26, 2014

Record last verified: 2014-08